DarioHealth (Nasdaq:DRIO) announced today that multiple research studies support its digital therapeutics for diabetes management.
New York-based DarioHealth presented the data from the new studies at the American Diabetes Association’s (ADA) 82nd Scientific Sessions in New Orleans. Two of the studies add to DarioHealth’s evidence supporting an integrated approach to managing multiple chronic conditions, while the third analyzed the impact across ethnicities of users living with type 2 diabetes.
“We are thrilled to present several new studies showcasing Dario’s ability to positively impact health and outcomes across a wide range of factors,” DarioHealth Scientific and Clinical Director and study supervisor Yifat Hershcovitz said in a news release. “Our deepening knowledge about the importance of an integrated solution approach has enormous potential to change the way people manage chronic conditions, and we are proud to share further insights with the scientific community this week.”
According to the release, one study examined a group of users with diabetes and stage 1 and above hypertension to understand the impact of using a single solution on both conditions. Results demonstrated significant improvements for both hypertension and diabetes at six months.
In the study, two-thirds of users improved their systolic blood pressure by 13 mmHg and diastolic by 8 mmHg, 38.7% lowered their hypertension by one stage and a subgroup of users with high-risk type 2 diabetes reduced average blood glucose readings by 15%.
The second study examined the outcomes of users living with high-risk diabetes and self-reported stress and/or depression and found that users reduced their average blood glucose by 13% after one year, highlighting how the company’s holistic support focused on behavior change can positively impact outcomes, DarioHealth said.
A third study looked at the impact on blood sugar readings in users with high-risk type 2 diabetes across ethnicities as reported in DarioHealth’s app: White, Black, Latino or Asian. The company observed that average blood glucose readings were significantly reduced by 14% for White users and 15% for Black, Latino and Asian users, highlighting the ability of the platform to improve self-care across diverse populations.
“Dario’s solutions are continuously proven to be highly effective across an ever-expanding set of conditions and circumstances,” DarioHealth CMO Dr. Omar Manejwala said. “Together, these studies offer a deeper understanding of the value Dario can provide to our users and partners through a single integrated platform.”
